Structure-based inhibitor design by using protein models for the development of antiparasitic agents

  1. C S Ring,
  2. E Sun,
  3. J H McKerrow,
  4. G K Lee,
  5. P J Rosenthal,
  6. I D Kuntz, and
  7. F E Cohen
  1. Department of Pharmaceutical Chemistry, University of California, San Francisco 94143-0446.

Abstract

The lack of an experimentally determined structure of a target protein frequently limits the application of structure-based drug design methods. In an effort to overcome this limitation, we have investigated the use of computer model-built structures for the identification of previously unknown inhibitors of enzymes from two major protease families, serine and cysteine proteases. We have successfully used our model-built structures to identify computationally and to confirm experimentally the activity of nonpeptidic inhibitors directed against important enzymes in the schistosome [2-(4-methoxybenzoyl)-1-naphthoic acid, Ki = 3 microM] and malaria (oxalic bis[(2-hydroxy-1-naphthylmethylene)hydrazide], IC50 = 6 microM) parasite life cycles.

« Previous | Next Article »Table of Contents